Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 09, 2026 17:15 ET | Source: Wintrust Financial Corporation

Wintrust Financial Corporation Announces Retirement of Board Members H. Patrick Hackett Jr. and William J. Doyle

CHICAGO, April 09, 2026 (GLOBE NEWSWIRE) -- Wintrust Financial Corporation (NASDAQ: WTFC) (“Wintrust”) today announced Board of Directors members H. Patrick Hackett Jr. and William J. Doyle will not...
April 09, 2026 17:09 ET | Source: National Music Centre

National Music Centre Announces Year-Long Celebration for 10th Anniversary at Studio Bell

Today, National Music Centre in Calgary officially launched its year-long 10th anniversary celebration.
April 09, 2026 16:30 ET | Source: OR Royalties Inc.

OR Royalties Announces Release of 2025 Sustainability Report

MONTRÉAL, April 09, 2026 (GLOBE NEWSWIRE) -- OR Royalties Inc. (“OR Royalties” or the “Company”) (OR: TSX & NYSE) announces the publication of its 2025 Sustainability Report, Growing...
April 09, 2026 16:25 ET | Source: eHealth Exchange

eHealth Exchange Demonstrates Real-World Patient Access Capability, Advancing CMS-Aligned Network Goals

VIENNA, Va., April 09, 2026 (GLOBE NEWSWIRE) -- eHealth Exchange™ today announced a major milestone toward becoming a CMS-Aligned Network with the successful enablement and live demonstration of...
April 09, 2026 16:25 ET | Source: Emergent BioSolutions

Emergent BioSolutions Partners with British Columbia to Supply NARCAN® Nasal Spray for the Launch of the Expanded BC Take Home Naloxone Program

WINNIPEG, Manitoba, April 09, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced that it has partnered with the B.C. Provincial Health Services Authority (PHSA) to supply...
April 09, 2026 16:21 ET | Source: Sobi, Inc.

Sobi Receives Health Canada Approval for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

EMPAVELI® (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced...